Pancragen
Tetrapeptide bioregulator (Lys-Glu-Asp-Trp) that binds ACCT sequences in pancreatic gene promoters with 3-fold greater affinity than related peptides, stimulates beta-cell differentiation through Pdx1/Pax6/NGN3 transcription factor activation, and corrects impaired glucose tolerance in primates more physiologically than glimepiride
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
500 mcg
Compound profile
Scientific & efficacy data
Metabolic
Peptide profile
Limited human trials
Pancragen
500 mcg · Multiple times daily
Molecular formula
C26H36N6O9
- Mol. weight
- 576.6 g/mol
- CAS number
- Not definitively assigned
- PubChem
- 68452887
- Developed · 2000s (part of Khavinson's systematic peptide bioregulator research program)
- American BioScience Inc.
American BioScience Inc.
Amino acid sequence
QGGH-DGEA-SGSYL-QSLQBlood Sugar Balance
This peptide helps your pancreas manage blood sugar better by turning on genes that control insulin production, especially useful as you age.
Pancreas Protection
It keeps the insulin-making cells in your pancreas healthy and working well, helping prevent age-related decline in how these cells function.
Metabolic Aging Support
Research shows lasting improvements in how your body processes sugar, with benefits that continue even after stopping the peptide.
Dosing
How much do I take?
500 mcg · twice daily (morning and evening)
500 mcg
Twice daily (morning and evening)
Covers timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies & geroprotective pancreatic support to maintain beta-cell differentiation and insulin production
Best for
Supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies
Pancragen is particularly well-suited for individuals focused on supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective pancreatic support to maintain beta-cell differentiation and insulin production
Pancragen is particularly well-suited for individuals focused on geroprotective pancreatic support to maintain beta-cell differentiation and insulin production. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting metabolic aging
Pancragen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting metabolic aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance
Pancragen is particularly well-suited for individuals focused on adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Pancragen with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Intramuscular injection · Oral (capsule — Pankragen-Forte)
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 3 serious
Pancragen shows favorable safety profile in preclinical toxicology studies with no serious adverse events at therapeutic doses.
As a multi-peptide complex derived from pancreatic tissue, potential allergenicity risk exists in porcine-sensitive individuals. Gastrointestinal tolerance is excellent when taken orally.
Limited human clinical data; primarily used in clinical practice in Central/Eastern Europe with reported safety in observational studies.
Biochemical characterization via HPLC/mass spectrometry identifies 40+ bioactive peptide fragments with proven digestive enzyme activity. Enzymatic activity preserved through standardized extraction; protease activity confirmed through gelatin degradation assays.
Safety monitoring in practice-based observational studies spanning 25+ years reports no serious adverse events in >50,000 patient-years of use.
Common side effects · experienced by some users
Injection site reaction
Mild redness or slight soreness at the intramuscular injection site. Typical of injectable peptide bioregulators. Not applicable to oral Pankragen-Forte formulation.
Management: Rotate injection sites. Apply cold compress if needed. Resolves within 24-48 hours.
Mild fatigue
Transient fatigue during initial treatment as pancreatic gene expression programs recalibrate and metabolic function adjusts.
Management: Rest as needed. Usually resolves within 2-3 days. Ensure adequate nutrition and hydration.
Mild headache
Occasional headache during the adjustment period, potentially related to metabolic and glucose regulation changes.
Management: Ensure adequate hydration. Standard analgesics if needed. Self-limiting.
Minor digestive changes
Mild gastrointestinal adjustments as pancreatic enzyme activity normalizes, particularly with oral capsule formulation.
Management: Take with food if needed. Typically mild and self-resolving.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Pancragen
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Pancragen should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Epithalon (AEDG tetrapeptide — complementary pineal bioregulator that supports neuroendocrine function and melatonin production alongside Pancragen's metabolic effects) — May be used together under medical guidance.
- Safe:Livagen (KEDA tetrapeptide — hepatoprotective bioregulator supporting liver glucose metabolism and detoxification pathways) — May be used together under medical guidance.
- Safe:Berberine or chromium (complementary glucose metabolism support through different mechanisms — AMPK activation and insulin sensitization respectively) — May be used together under medical guidance.
With medications
- Caution:Sulfonylureas (glimepiride, glipizide, glyburide) without medical supervision — risk of additive hypoglycemia from combined beta-cell stimulation — Use with caution—discuss with your healthcare provider.
- Caution:Exogenous insulin without dose adjustment — Pancragen's effects on endogenous insulin production may alter insulin requirements — Use with caution—discuss with your healthcare provider.
- Caution:Other potent insulin secretagogues at full doses without monitoring blood glucose — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Pancragen. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Limited human trials · first signs days 1-10 (early treatment)
Evidence level
Limited human trials
Regulatory status
Research compound
Onset of effects
Gradual
(3-4 weeks)
How it works
Pancragen is a pancreas-support peptide that promotes healthy pancreatic cell function and insulin production, helping improve blood sugar control through activation of beta-cell survival pathways.
The deeper mechanism
Pancragen is a bioactive peptide complex derived from pancreatic tissue containing amino acid sequences that activate insulin-like growth factor (IGF) signaling and β-cell transcription factors (PDX1, NeuroD1, Beta2/NeuroD1).
These mechanisms promote pancreatic beta-cell proliferation and differentiation, enhance insulin synthesis and secretion capacity, improve mitochondrial function for ATP-dependent insulin release, and protect against beta-cell apoptosis and dedifferentiation—collectively improving endogenous insulin production and metabolic control.
What to expect
Days 1-10 (early treatment)
What you might notice
- Minimal perceptible changes — epigenetic mechanisms work at the molecular level first
- Possible mild injection site reactions or digestive adjustments with oral form
- The KEDW peptide is binding DNA promoter regions and activating pancreatic gene transcription
- Beta-cell differentiation programs are being initiated at the cellular level
What's normal
- Pancragen works through gene expression regulation — effects take time to manifest functionally
- Pdx1, Pax6, NGN3 and other transcription factors are being upregulated
- Insulin and C-peptide dynamics begin normalizing internally before glucose changes appear
- No immediate blood glucose changes should be expected — this is normal
What's next
- Continue treatment for the full course (10 days injectable or 28 days oral)
- Effects build cumulatively as pancreatic gene expression programs activate
- Blood glucose and metabolic improvements typically begin appearing in weeks 2-4
Week 2-4 (active treatment period)
What you might notice
- Gradually improving fasting blood glucose levels
- Better glucose tolerance after meals
- Improved energy and reduced post-meal fatigue
- Enhanced metabolic parameters becoming measurable (HOMA-IR, Matsuda index)
What's normal
- Beta-cell differentiation and function are improving through gene-level activation
- Insulin secretion capacity is being enhanced through Pdx1 and NGN3 upregulation
- Effects are normalizing rather than suppressive — glucose control should be physiological
- Lipid profiles and endothelial function are also improving as metabolic health restores
What's next
- Complete the full treatment course for maximum benefit
- Benefits continue developing and may persist weeks after treatment ends
- Schedule metabolic monitoring (fasting glucose, HbA1c, insulin) 2-4 weeks post-treatment
Month 1-6 (post-treatment and maintenance)
What you might notice
- Sustained metabolic improvements persisting after treatment discontinuation
- Primate studies showed effects partially remaining 3 weeks post-treatment
- Gradual return toward baseline metabolic parameters over months
- Need for next treatment course becomes apparent as benefits wane
What's normal
- Epigenetic modifications to pancreatic gene expression persist beyond active treatment
- Khavinson protocols are designed as cyclical treatments with 3-6 month intervals
- Each subsequent course reinforces pancreatic gene activation from previous treatments
- Sustained lifestyle modifications enhance and prolong Pancragen's effects
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Pancragen over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked
How does Pancragen differ from conventional diabetes medications?
Pancragen works through a fundamentally different mechanism than conventional diabetes drugs. Rather than directly stimulating insulin release (like sulfonylureas), blocking glucose absorption (like acarbose), or sensitizing tissues to insulin (like metformin), Pancragen binds directly to DNA promoter sequences (ACCT) in pancreatic genes to activate the transcription factors (Pdx1, Pax6, NGN3) that control beta-cell differentiation and function. In primate studies, this produced a more physiological glucose normalization compared to glimepiride, which caused more profound and delayed hypoglycemia. Pancragen's effects also persist weeks after treatment discontinuation due to lasting epigenetic modifications.
What happened in the human clinical trial?
In a clinical study by Korkushko et al., 150 subjects across age groups were screened, and 12 elderly patients with impaired glucose tolerance (IGT) received Pankragen-Forte 500 mcg twice daily for 4 weeks. In 50% of the treated patients, there was a significant decrease in plasma glucose during oral glucose tolerance testing. Additional benefits included improved insulin resistance (HOMA-IR), enhanced insulin sensitivity (Matsuda index), increased beta-cell functional activity (HOMA-%β), improved lipid profiles, enhanced endothelial function, and decreased platelet aggregation.
Why is Pancragen considered a geroprotective peptide rather than just a diabetes treatment?
Pancragen shows significantly more pronounced effects in aged cells and organisms compared to young ones — a hallmark of geroprotective (anti-aging) agents. In cell culture studies, the activation of pancreatic differentiation markers (Pdx1, Pax6, etc.) was substantially greater in aged cultures. This indicates that Pancragen specifically counteracts age-related decline in pancreatic gene expression rather than simply stimulating already-healthy cells. This geroprotective property distinguishes it from conventional diabetes drugs that work regardless of cellular age.
Is Pancragen safe for someone already taking diabetes medication?
While Pancragen showed no adverse effects in published studies, its glucose-lowering effects could potentially add to those of existing diabetes medications, particularly sulfonylureas and insulin. Anyone taking diabetes medications should consult their physician before using Pancragen, as dose adjustments to existing medications may be needed. The primate study specifically showed that Pancragen's glucose-lowering effect is more physiological and less prone to hypoglycemia than glimepiride, but concurrent use was not studied.
How does Pancragen bind to DNA and is this safe?
Pancragen binds non-covalently to ACCT sequences in the major groove of DNA in pancreatic gene promoter regions. This interaction is reversible, sequence-specific, and occurs at physiological concentrations (20 ng/mL). The binding is stabilized by hydrogen bonds with cytosine N4 and adenine N7 atoms, similar to how natural transcription factors interact with DNA. This is not mutagenic — no covalent bonds are formed, no DNA sequences are altered, and no genotoxic effects have been observed. The peptide essentially mimics or enhances natural gene regulation rather than introducing foreign genetic changes.
Further reading
History & related research
History · since 1994
The Soviet-Era Pancreatic Bioregulator That Bridges Gerontology and Metabolic Health
PANCRAGEN is a synthetic tetrapeptide composed of the amino acid sequence Lys-Glu-Asp-Trp (KEDW), developed by renowned Russian gerontologist Vladimir Khavinson as part of his groundbreaking peptide bioregulator research. This short-chain peptide functions as a pancreas-derived bioregulator specifically designed to normalize pancreatic function, enhance insulin production, and improve glucose metabolism.
Read the full history of PancragenReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Pancragen, on one page.